SARAH ANSBRO: Open Payments
NPI 1063702637 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,517 in 82 payments from 11 companies in 2025. Trend: 2023 $773 · 2024 $922 · 2025 $1,517
Food & beverage: $1,517
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $380 |
| Supernus Pharmaceuticals, Inc. | 11 | $277 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $227 |
| Otsuka America Pharmaceutical, Inc. | 13 | $193 |
| Axsome Therapeutics, Inc. | 7 | $155 |
| Teva Pharmaceuticals USA, Inc. | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $83 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: VRAYLAR, Qelbree, CAPLYTA, REXULTI, Auvelity, AUSTEDO XR, COBENFY, FANAPT.
Industry payments across TX — which companies pay providers there.
